Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.07
ENDP's Cash to Debt is ranked lower than
93% of the 791 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.03 vs. ENDP: 0.07 )
Ranked among companies with meaningful Cash to Debt only.
ENDP' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 1.35 Max: No Debt
Current: 0.07
Equity to Asset 0.34
ENDP's Equity to Asset is ranked lower than
85% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ENDP: 0.34 )
Ranked among companies with meaningful Equity to Asset only.
ENDP' s Equity to Asset Range Over the Past 10 Years
Min: 0.08  Med: 0.55 Max: 0.77
Current: 0.34
0.08
0.77
F-Score: 4
Z-Score: 0.08
M-Score: -2.80
WACC vs ROIC
1.52%
2.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -9.90
ENDP's Operating margin (%) is ranked lower than
78% of the 737 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.69 vs. ENDP: -9.90 )
Ranked among companies with meaningful Operating margin (%) only.
ENDP' s Operating margin (%) Range Over the Past 10 Years
Min: -28.56  Med: 23.74 Max: 30.74
Current: -9.9
-28.56
30.74
Net-margin (%) -3.32
ENDP's Net-margin (%) is ranked lower than
75% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. ENDP: -3.32 )
Ranked among companies with meaningful Net-margin (%) only.
ENDP' s Net-margin (%) Range Over the Past 10 Years
Min: -45.74  Med: 11.26 Max: 20.95
Current: -3.32
-45.74
20.95
ROE (%) -2.09
ENDP's ROE (%) is ranked lower than
71% of the 764 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. ENDP: -2.09 )
Ranked among companies with meaningful ROE (%) only.
ENDP' s ROE (%) Range Over the Past 10 Years
Min: -85.73  Med: 12.36 Max: 20.43
Current: -2.09
-85.73
20.43
ROA (%) -0.67
ENDP's ROA (%) is ranked lower than
68% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. ENDP: -0.67 )
Ranked among companies with meaningful ROA (%) only.
ENDP' s ROA (%) Range Over the Past 10 Years
Min: -10.68  Med: 5.72 Max: 14.68
Current: -0.67
-10.68
14.68
ROC (Joel Greenblatt) (%) -57.58
ENDP's ROC (Joel Greenblatt) (%) is ranked lower than
81% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. ENDP: -57.58 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ENDP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -117.88  Med: 141.4 Max: 718.27
Current: -57.58
-117.88
718.27
Revenue Growth (3Y)(%) -12.00
ENDP's Revenue Growth (3Y)(%) is ranked lower than
86% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.50 vs. ENDP: -12.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ENDP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -12  Med: 20.3 Max: 26.9
Current: -12
-12
26.9
EBITDA Growth (3Y)(%) -1.50
ENDP's EBITDA Growth (3Y)(%) is ranked lower than
69% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.00 vs. ENDP: -1.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ENDP' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -10  Med: 16.6 Max: 75.9
Current: -1.5
-10
75.9
EPS Growth (3Y)(%) -36.70
ENDP's EPS Growth (3Y)(%) is ranked lower than
89% of the 540 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.20 vs. ENDP: -36.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ENDP' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 9.95 Max: 81.7
Current: -36.7
0
81.7
GuruFocus has detected 4 Warning Signs with Endo International PLC $ENDP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ENDP's 10-Y Financials

Financials (Next Earnings Date: 2017-02-28)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ENDP Guru Trades in Q1 2016

Jim Simons 569,260 sh (New)
David Dreman 792 sh (New)
Paul Tudor Jones 64,148 sh (+700.95%)
John Paulson 9,517,500 sh (+188.22%)
RS Investment Management 1,368,053 sh (+151.67%)
Wallace Weitz 968,093 sh (+41.34%)
George Soros 103,200 sh (unchged)
John Paulson 119,900 sh (unchged)
Louis Moore Bacon Sold Out
John Griffin Sold Out
George Soros Sold Out
Mario Gabelli Sold Out
Andreas Halvorsen 4,468,744 sh (-1.15%)
Diamond Hill Capital 12,443 sh (-8.28%)
Pioneer Investments 140,434 sh (-38.71%)
Steven Cohen 228,000 sh (-42.50%)
» More
Q2 2016

ENDP Guru Trades in Q2 2016

Arnold Schneider 445,225 sh (New)
Joel Greenblatt 1,036,004 sh (New)
David Dreman 10,670 sh (+1247.22%)
Steven Cohen 2,521,434 sh (+1005.89%)
RS Investment Management 1,374,185 sh (+0.45%)
John Paulson 119,900 sh (unchged)
Andreas Halvorsen Sold Out
Diamond Hill Capital Sold Out
Wallace Weitz Sold Out
John Paulson 8,956,300 sh (-5.90%)
Paul Tudor Jones 17,296 sh (-73.04%)
Pioneer Investments 28,618 sh (-79.62%)
Jim Simons 11,005 sh (-98.07%)
» More
Q3 2016

ENDP Guru Trades in Q3 2016

Mario Gabelli 46,700 sh (New)
Larry Robbins 4,250,784 sh (New)
Ray Dalio 887,293 sh (New)
Jim Simons 206,060 sh (+1772.42%)
Paul Tudor Jones 59,815 sh (+245.83%)
Arnold Schneider 479,006 sh (+7.59%)
Pioneer Investments 28,618 sh (unchged)
David Dreman 10,670 sh (unchged)
John Paulson 7,953,900 sh (-11.19%)
Steven Cohen 1,762,300 sh (-30.11%)
Joel Greenblatt 28,677 sh (-97.23%)
» More
Q4 2016

ENDP Guru Trades in Q4 2016

Jim Simons 1,525,860 sh (+640.49%)
Ray Dalio 1,537,036 sh (+73.23%)
Arnold Schneider 559,211 sh (+16.74%)
Mario Gabelli 47,500 sh (+1.71%)
Pioneer Investments 28,618 sh (unchged)
Larry Robbins 4,250,784 sh (unchged)
Steven Cohen Sold Out
David Dreman Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
John Paulson 7,839,900 sh (-1.43%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ENDP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:SHPHF, NAS:HZNP, NAS:AKRX, NAS:IRWD, OTCPK:INVVY, NYSE:CTLT, NAS:MDCO, OTCPK:STDAF, NAS:NBIX, NAS:RDUS, NAS:PCRX, NAS:MNTA, NAS:SUPN, NYSE:PTHN, OTCPK:KHTRF, OTCPK:GNMLF, OTCPK:TWMJF, NAS:EGRX, NAS:SGYP, NAS:IPXL » details
Traded in other countries:ENDP.Canada, EO7.Germany,
Endo International PLC is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products as well as medical devices.

Endo International PLC was incorporated in Ireland on October 31, 2013. It is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products as well as medical devices. The Compnay's business segments are U.S. Branded Pharmaceuticals, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded Pharmaceuticals segment includes a variety of branded prescription products related to treating and managing pain as well as its urology and men's health, endocrinology and orthopedic products. The marketed products that are included in this segment include Lidoderm, OPANA ER, Voltaren Gel, Percocet, BELBUCA, Fortesta Gel, Testim, Aveed, Supprelin LA, and XIAFLEX. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including high barrier to entry products, first to file or first to market opportunities, that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The product offerings of this segment include products in the pain management, urology, CNS disorders, immunosuppression, oncology, women's health and cardiovascular disease markets. The International Pharmaceuticals segment includes a variety of specialty pharmaceutical products for the Canadian, Mexican, South African and world markets. Paladin, based in Canada, has a portfolio of products serving growing therapeutic areas, including ADHD, pain, women's health and oncology. Somar, based in Mexico, develops, manufactures and markets high-quality generic, branded generic and over-the-counter products across key market segments including dermatology and anti-infectives. Litha, based in South Africa, is a diversified healthcare group providing services, products and solutions to public and private hospitals, pharmacies, general and specialist practitioners, as well as government healthcare programs. The Company's competitors include Abbott Laboratories, Allergan plc, Purdue Pharma, L.P., Jazz Pharmaceuticals plc, Shire plc, Horizon Pharma plc, and Mallinckrodt plc, Teva Pharmaceutical Industries, Mylan, Inc., and Impax Laboratories, Inc. The Company has 352 U.S. issued patents, 190 U.S. patent applications pending, 856 foreign issued patents, and 510 foreign patent applications pending. It also has licenses for 81 U.S. issued patents, 56 U.S. patent applications pending, 334 foreign issued patents and 139 foreign patent applications pending. In the United States, the development, testing, manufacture, holding, packaging, labeling, distribution, marketing, and sales of its products and the ongoing product development activities are subject to and rigorous government regulation.

Guru Investment Theses on Endo International PLC

Weitz Funds Comments on Endo International - Jan 26, 2017

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital in more attractive opportunities.



From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Wally Weitz Comments on Endo - Nov 08, 2016

Endo (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital in more attractive opportunities.

From Wallace Weitz (Trades, Portfolio)'s Partners Value Fund third-quarter commentary.

Check out Wallace Weitz latest stock trades

Weitz Funds Comments on Endo International - Jul 20, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse than anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly and we were slow to recognize it. After conversations with management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Given the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position and refocus our capital in more attractive opportunities.



From Weitz Value Fund's Value second quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Endo International - Apr 22, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded and generic pharmaceutical products and medical devices. Several developments contributed to a difficult 12-month period for Endo’s stock. Growth in the company’s branded drug division has been disappointing, owing in part to poor results from several drugs Endo inherited from its acquisition of Auxilium Pharmaceuticals roughly ayear ago. In addition, pricing pressure in the company’s legacy Qualitest generics business increased, muting the segment’s near-term (and potentially long-term) growth trajectory. Finally, liabilities relating to the company’s legacy vaginal mesh products increased, following an influx of claims late in 2015. While our business value estimate for Endo has come down, the stock price has declined far more significantly. Using conservative assumptions for the company’s business over the next several years, we believe Endo has significant upside potential if management can execute on its growth plans for XIAFLEX (attractive injectible franchise) and BELBUCA (pain patch).

From Wallace Weitz (Trades, Portfolio)'s Weitz Value Fund 1st quarter 2016 commentary.

Check out Wallace Weitz latest stock trades

Wallace Weitz Comments on Endo International - Jan 22, 2016

Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Amid widespread pressure in the pharmaceutical market, news at Endo was mixed during the quarter. The company recorded a significant impairment charge in November relating to its recent acquisition of Auxilium. While management had hinted at some early challenges with Auxilium’s topical testosterone products and STENDRA (a competitor to Viagra in the ED market), CEO Rajiv De Silva formally announced Endo would be de-emphasizing and/or selling these products. This decision increases Endo’s dependence upon its primary growth drivers (recently acquired Par Pharmaceutical, Xiaflex and new pain product BELBUCA), which we believe will drive attractive organic sales growth during the next several years. News of a renewed 8-year commercial agreement with Novartis for Voltaren Gel was a distinct positive. We added to our position below $60 per share during the quarter.

From Wallace Weitz (Trades, Portfolio)'s fourth quarter 2015 Value Fund commentary.

Check out Wallace Weitz latest stock trades

Top Ranked Articles about Endo International PLC

Weitz Funds Comments on Endo International Guru stock highlight
Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital in more attractive opportunities. Read more...
Wally Weitz Comments on Endo Guru stock highlight
Endo (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse-than-anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly, and we were slow to recognize it. After conversations with both management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Considering the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position in the second calendar quarter and refocus our capital Read more...
Healthcare Growth Stocks in the S&P 500: Part 2 Weakness in the healthcare sector has created buying opportunities in 7 companies
Introduction Read more...
Healthcare Growth Stocks in the S&P 500: Part 2 Weakness in the healthcare sector has created buying opportunities with 7 companies
Introduction Read more...
Weitz Funds Comments on Endo International Guru stock highlight
Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded pharmaceutical and generic products and medical devices. Endo experienced significantly worse than anticipated erosion at Qualitest, its legacy generic drug platform. Simply put, our analysis of the company’s competitive positioning in controlled substance generics was wrong. The competitive environment changed quickly and we were slow to recognize it. After conversations with management and a couple of the larger drug buying consortiums, we could not gain comfort in the durability of Endo’s now lower earnings base. The company’s balance sheet and potential legal obligations (liabilities relating to the company’s legacy vaginal mesh products) leave less room for error given growth challenges on the branded side of Endo’s business. Given the erosion in our investment thesis, questions about management’s ability to identify and navigate risk, and a growing list of unknowns surrounding the business, we elected to close our position and refocus our capital in more attractive opportunities.
From Read more...
Wally Weitz Drops Falling Drug Stock Endo but Sees 'Upside Potential' Possibly short-term headwinds prompted 75 percent market sell-off this year
Wally Weitz, founder and chief investment officer of Weitz Investment Management, informed clients via a one-off note Thursday that his firm exited it entire position in pharmaceutical company Endo International, whose stock has dwindled to a quarter of its market value year to date. Read more...
Wallace Weitz Comments on Endo International Guru stock highlight
Endo International (NASDAQ:ENDP) is a specialty healthcare company engaged in developing, manufacturing, marketing and distributing branded and generic pharmaceutical products and medical devices. Several developments contributed to a difficult 12-month period for Endo’s stock. Growth in the company’s branded drug division has been disappointing, owing in part to poor results from several drugs Endo inherited from its acquisition of Auxilium Pharmaceuticals roughly ayear ago. In addition, pricing pressure in the company’s legacy Qualitest generics business increased, muting the segment’s near-term (and potentially long-term) growth trajectory. Finally, liabilities relating to the company’s legacy vaginal mesh products increased, following an influx of claims late in 2015. While our business value estimate for Endo has come down, the stock price has declined far more significantly. Using conservative assumptions for the company’s business over the next several years, we believe Endo has significant upside potential if management can execute on its growth plans for XIAFLEX (attractive injectible franchise) and BELBUCA (pain Read more...

Ratios

vs
industry
vs
history
Forward P/E 3.08
ENDP's Forward P/E is ranked higher than
99% of the 88 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.46 vs. ENDP: 3.08 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 4.46
ENDP's PE(NRI) is ranked higher than
96% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.84 vs. ENDP: 4.46 )
Ranked among companies with meaningful PE(NRI) only.
ENDP' s PE(NRI) Range Over the Past 10 Years
Min: 4.02  Med: 18.99 Max: 1083
Current: 4.46
4.02
1083
P/B 0.48
ENDP's P/B is ranked higher than
97% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. ENDP: 0.48 )
Ranked among companies with meaningful P/B only.
ENDP' s P/B Range Over the Past 10 Years
Min: 0.43  Med: 2.54 Max: 17.5
Current: 0.48
0.43
17.5
P/S 0.73
ENDP's P/S is ranked higher than
89% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. ENDP: 0.73 )
Ranked among companies with meaningful P/S only.
ENDP' s P/S Range Over the Past 10 Years
Min: 0.66  Med: 2.34 Max: 6
Current: 0.73
0.66
6
PFCF 5.59
ENDP's PFCF is ranked higher than
95% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.72 vs. ENDP: 5.59 )
Ranked among companies with meaningful PFCF only.
ENDP' s PFCF Range Over the Past 10 Years
Min: 4.69  Med: 9.46 Max: 250.64
Current: 5.59
4.69
250.64
POCF 4.08
ENDP's POCF is ranked higher than
94% of the 295 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.98 vs. ENDP: 4.08 )
Ranked among companies with meaningful POCF only.
ENDP' s POCF Range Over the Past 10 Years
Min: 3.68  Med: 9.16 Max: 212.54
Current: 4.08
3.68
212.54
EV-to-EBITDA 18.86
ENDP's EV-to-EBITDA is ranked lower than
56% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.72 vs. ENDP: 18.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENDP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -139  Med: 9 Max: 29.3
Current: 18.86
-139
29.3
Current Ratio 0.84
ENDP's Current Ratio is ranked lower than
90% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. ENDP: 0.84 )
Ranked among companies with meaningful Current Ratio only.
ENDP' s Current Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.9 Max: 3.55
Current: 0.84
0.84
3.55
Quick Ratio 0.61
ENDP's Quick Ratio is ranked lower than
89% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. ENDP: 0.61 )
Ranked among companies with meaningful Quick Ratio only.
ENDP' s Quick Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.64 Max: 3.34
Current: 0.61
0.61
3.34
Days Inventory 98.09
ENDP's Days Inventory is ranked higher than
59% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. ENDP: 98.09 )
Ranked among companies with meaningful Days Inventory only.
ENDP' s Days Inventory Range Over the Past 10 Years
Min: 80.55  Med: 102.16 Max: 148.08
Current: 98.09
80.55
148.08
Days Sales Outstanding 63.63
ENDP's Days Sales Outstanding is ranked higher than
60% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.32 vs. ENDP: 63.63 )
Ranked among companies with meaningful Days Sales Outstanding only.
ENDP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.33  Med: 108.55 Max: 171.52
Current: 63.63
71.33
171.52
Days Payable 41.56
ENDP's Days Payable is ranked lower than
75% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. ENDP: 41.56 )
Ranked among companies with meaningful Days Payable only.
ENDP' s Days Payable Range Over the Past 10 Years
Min: 60.54  Med: 151.89 Max: 300.35
Current: 41.56
60.54
300.35

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -26.10
ENDP's 3-Year Average Share Buyback Ratio is ranked lower than
86% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. ENDP: -26.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ENDP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.1  Med: -0.6 Max: 4.7
Current: -26.1
-26.1
4.7

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 0.35
ENDP's Price/Projected FCF is ranked higher than
97% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. ENDP: 0.35 )
Ranked among companies with meaningful Price/Projected FCF only.
ENDP' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.39  Med: 0.73 Max: 2.28
Current: 0.35
0.39
2.28
Price/Median PS Value 0.31
ENDP's Price/Median PS Value is ranked higher than
96% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. ENDP: 0.31 )
Ranked among companies with meaningful Price/Median PS Value only.
ENDP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.38  Med: 1.36 Max: 3.54
Current: 0.31
0.38
3.54
Earnings Yield (Greenblatt) (%) -3.80
ENDP's Earnings Yield (Greenblatt) (%) is ranked lower than
77% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. ENDP: -3.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ENDP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.3  Med: 8.35 Max: 26.8
Current: -3.8
1.3
26.8
Forward Rate of Return (Yacktman) (%) 39.83
ENDP's Forward Rate of Return (Yacktman) (%) is ranked higher than
90% of the 358 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.67 vs. ENDP: 39.83 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ENDP' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 4.3  Med: 30.6 Max: 63.3
Current: 39.83
4.3
63.3

More Statistics

Revenue (TTM) (Mil) $3,842
EPS (TTM) $ -0.31
Beta-0.18
Short Percentage of Float10.14%
52-Week Range $11.37 - 54.79
Shares Outstanding (Mil)222.88

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 3,929 3,881 3,744 3,773
EPS ($) 4.36 4.41 4.35 4.29
EPS w/o NRI ($) 4.36 4.41 4.35 4.29
EPS Growth Rate
(3Y to 5Y Estimate)
0.69%
Dividends Per Share ($)
» More Articles for ENDP

Headlines

Articles On GuruFocus.com
Weitz Funds Comments on Endo International Jan 26 2017 
4 Stocks Reach Their 3-Year Lows Jan 21 2017 
Wally Weitz Comments on Endo Nov 08 2016 
Wally Weitz's Partners Value Fund 3rd Quarter Commentary Nov 08 2016 
Healthcare Growth Stocks in the S&P 500: Part 2 Aug 12 2016 
Healthcare Growth Stocks in the S&P 500: Part 2 Aug 12 2016 
US Market Indexes Reach New Highs Aug 09 2016 
Weitz Funds Comments on Endo International Jul 20 2016 
Wally Weitz's Partners Value Fund 2Q 2016 Quarterly Commentary Jul 20 2016 
10 Biotech and Specialty Pharma Bargains: Do You Have the Guts to Speculate? Jul 01 2016 

More From Other Websites
Endo to Announce Fourth-Quarter and Full-Year 2016 Financial Results Feb 13 2017
Endo to Announce Fourth-Quarter and Full-Year 2016 Financial Results Feb 13 2017
Is More Downside Ahead For Teva Pharmaceutical? Feb 10 2017
Canada's TMX seeks part of Saudi Aramco listing Feb 08 2017
Canada's TMX seeks part of Saudi Aramco listing Feb 08 2017
Belbuca return expected to push BDSI to profitability sooner Feb 01 2017
Endo's (ENDP) Ephedrine Sulfate Injection Gets FDA Approval Jan 31 2017
Endo International: We Believe? Jan 31 2017
Endo Announces U.S. FDA Approval of Ephedrine Sulfate Injection, USP Jan 30 2017
Endo Announces U.S. FDA Approval of Ephedrine Sulfate Injection, USP Jan 30 2017
Endo (ENDP) Restructures Branded Pharmaceutical Unit (revised) Jan 30 2017
Endo (ENDP) Restructures its Branded Pharmaceutical Unit Jan 27 2017
New Strong Sell Stocks for January 27th Jan 27 2017
Weitz Funds Comments on Endo International Jan 26 2017
Endo to cut 90 jobs as part of drugmaker's restructuring Jan 26 2017
ENDO INTERNATIONAL PLC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities,... Jan 26 2017
Endo Announces Actions to Drive Greater Efficiency and Business Alignment Jan 26 2017
Endo Announces Actions to Drive Greater Efficiency and Business Alignment Jan 26 2017
Endo Settles FTC 'Pay-for-Delay' Allegations Jan 25 2017
Endo (ENDP) Settles Disputes with Federal Trade Commission Jan 24 2017
Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo Jan 24 2017
U.S. reaches settlement with Endo on pay-for-delay charges Jan 23 2017
Endo Resolves FTC Antitrust Suit, But Allergan Hanging; Stocks Mixed Jan 23 2017
Endo Announces Appointments and Updates to Executive Management Team Dec 21 2016
Endo Announces Appointment of Blaise Coleman as Chief Financial Officer Dec 20 2016
Endo Reports Third Quarter 2016 Financial Results Nov 08 2016
Endo Strengthens Leadership Team with Appointment of Two Key Executives Nov 07 2016
Endo Begins Shipment of Generic SEROQUEL XR® Nov 01 2016
Endo Announces Departure of Chief Financial Officer Oct 20 2016
Endo to Announce Third Quarter 2016 Financial Results on November 8, 2016 Oct 18 2016
Endo Pharmaceuticals Presents New Phase 2 Data Evaluating the Safety and Effectiveness of XIAFLEX®... Sep 30 2016
Endo Names Paul Campanelli President and Chief Executive Officer Sep 23 2016
Endo's President and CEO Adopts 10b5-1 Trading Plan Aug 18 2016
Endo Announces OPANA® ER Regulatory Update Aug 12 2016
US STOCKS-Nasdaq hits record high, other indexes hover near highs Aug 09 2016
US STOCKS-Wall Street catches its breath after recent rally Aug 09 2016
Endo Reports Second Quarter 2016 Financial Results Aug 08 2016
Endo Announces Appointment of Joseph J. Ciaffoni as President, U.S. Branded Pharmaceuticals Aug 08 2016
Endo Announces Issuance of Vasostrict® Patent Jun 28 2016
Exclusive: Speciality drugmaker Endo explores asset sales - sources Jun 27 2016
Exclusive: Specialty drugmaker Endo explores asset sales - sources Jun 27 2016
Endo Announces FDA Advisory Committee Meeting For OPANA® ER Jun 15 2016
Endo Announces Local Qualitest Scholarship Program Award Recipients Jun 10 2016
Robbins Arroyo LLP: Endo International plc (ENDP) Misled Shareholders According to a Recently Filed... Jun 02 2016
US STOCKS-Wall St ends up after jobs report; S&P down for 2nd week May 06 2016
Endo Announces Appointment of Douglas S. Ingram and Todd B. Sisitsky to its Board of Directors May 05 2016
Endo Reports First Quarter 2016 Financial Results May 05 2016
Endo Announces Change to Senior Management Team May 05 2016
Endo Announces Appearances at Upcoming Conferences May 03 2016
U.S. FTC sues Endo alleging antitrust violations Mar 31 2016
Endo to flag Opana ER painkiller's risks, under NY settlement Mar 03 2016
Endo to flag Opana ER painkiller's risks, under NY settlement Mar 03 2016
US STOCKS-Wall St edges up on China stimulus, higher oil prices Feb 29 2016
US STOCKS-Wall St up slightly on China stimulus, oil price rise Feb 29 2016
Mylan-targeted Perrigo held merger talks with Endo - sources Nov 12 2015
Analysis - Valeant plunge spotlights cracks in specialty pharma's M&A facade Oct 21 2015
Hikma to buy Boehringer's U.S. generic drug business for $2.65 billion Jul 28 2015
Hikma to buy Boehringer's U.S. generic drug business for $2.65 bln Jul 28 2015
US HY CLOSE-CNH raises US$600m; Summit to price later Jun 23 2015
US HY CLOSE-Two high-yield issuers tap market for US$2bn Jun 22 2015
Pozen to redomicile as it agrees to buy Tribute Pharmaceuticals Jun 08 2015
Dow, S&P 500 close at record highs May 18 2015
US STOCKS-Dow, S&P close at record highs as rate-hike angst abates May 18 2015
Abandoning Par IPO for $8 billion sale could help TPG with its own May 18 2015
US STOCKS-Dow, S&P hit record highs as rate-hike worries fade May 18 2015
Endo pushes further into generics with $8 billion Par Pharma buy May 18 2015
Endo pushes further into generics with $8 bln Par Pharma buy May 18 2015
US STOCKS-Dow, S&P touch record highs May 18 2015
US STOCKS-Wall St down as homebuilder confidence slips May 18 2015
Endo to buy Par Pharmaceutical for $8.05 bn May 18 2015
US STOCKS-Wall St opens mixed ahead of homebuilder sentiment data May 18 2015
Endo withdraws offer for Salix Mar 16 2015
Analysis - Endo's bid for Salix shows its strategy as Valeant challenger Mar 12 2015
Endo offers about $11 billion for Salix, trumping Valeant Mar 11 2015
Drugmaker Valeant close to buying Salix - source Feb 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)